Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2024-N-5964]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA or Agency) is withdrawing approval of 23 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
 DATES: Approval is withdrawn as of February 14, 2025.
 FOR FURTHER INFORMATION CONTACT: Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 301-796-3471, 
                        *Martha.Nguyen@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: The applicants listed in table 1 have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. Table 1—ANDAs for Which Approval Is Withdrawn
Application No.
Drug
ApplicantANDA 040454
Promethazine Hydrochloride (HCl) injectable, 25 milligrams (mg)/milliliters (mL) and 50 mg/mL
Teva Pharmaceuticals USA, Inc., 400 Interpace Parkway, Bldg. A, Parsippany, NJ 07054.ANDA 040593
Promethazine HCl injectable, 25 mg/mL and 50 mg/mL
Sandoz Inc., 100 College Rd. West, Princeton, NJ 08540.ANDA 064042
Nystatin suspension, 100,000 units/mL
PAI Holdings, LLC, dba Pharmaceutical Associates, Inc., and dba PAI Pharma, 1700 Perimeter Rd., Greenville, SC 29605.ANDA 074811
Haloperidol Decanoate injectable, Equivalent to (EQ) 50 mg base/mL
Hikma Pharmaceuticals USA Inc., 2 Esterbrook Lane, Cherry Hill, NJ 08003.ANDA 076061
Pergolide Mesylate tablet, EQ 0.05 mg base, EQ 0.25 mg base, and EQ 1 mg base
Strides Pharma Inc., U.S. Agent for Strides Pharma Global Pte Ltd., 2 Tower Center Blvd., Suite 1102, East Brunswick, NJ 08816.ANDA 079075
Fentanyl Citrate tablet, EQ 0.1 mg base, EQ 0.2 mg base, EQ 0.4 mg base, EQ 0.6 mg base, and EQ 0.8 mg base
Watson Laboratories, Inc. (an indirect, wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.), 400 Interpace Parkway, Bldg. A, Parsippany, NJ 07054.ANDA 079240
Sumatriptan Succinate injectable, EQ 6 mg base/0.5 mL (EQ 12 mg base/mL) and EQ 4 mg base/0.5 mL (EQ 8 mg base/mL)
Fresenius Kabi USA, LLC, Three Corporate Dr., Lake Zurich, IL 60047.ANDA 084591
Promethazine HCl injectable, 25 mg/mL
Watson Laboratories, Inc. (an indirect, wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.).ANDA 090016
Irinotecan HCl injectable, 40 mg/2mL (20 mg/mL) and 100 mg/5 mL (20 mg/mL)
Hisun Pharmaceuticals USA Inc., U.S. Agent for Hisun Pharmaceutical (Hangzhou) Co., Ltd., 200 Crossing Blvd., 2nd Floor, Bridgewater, NJ 08807.ANDA 200536
Ranitidine HCl tablet, EQ 150 mg base
Strides Pharma Inc., U.S. Agent for Strides Pharma Global Pte Ltd.ANDA 201745
Ranitidine HCl tablet, EQ 75 mg base
Do.ANDA 204991
Atorvastatin Calcium tablet, EQ 10 mg base, EQ 20 mg base, EQ 40 mg base, and EQ 80 mg base
Lupin Pharmaceuticals, Inc., U.S. Agent for Lupin Ltd., Harborplace Tower, 111 South Calvert St., 21st Floor, Baltimore, MD 21202.ANDA 205512
Ranitidine HCl tablet, EQ 150 mg base and EQ 300 mg base
Strides Pharma Inc., U.S. Agent for Strides Pharma Global Pte Ltd.ANDA 206155
Olanzapine tablet, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg
RegCon Solutions, LLC, U.S. Agent for Indoco Remedies Ltd., 9920 Pacific Heights Blvd., Suite 250, San Diego, CA 92121.ANDA 206204
Piperacillin and Tazobactam injectable, EQ 12 grams (g) base/vial; EQ 1.5 g base/vial
Fresenius Kabi USA, LLC.ANDA 207338
Fentanyl Citrate tablet, EQ 0.1 mg base, EQ 0.2 mg base, EQ 0.3 mg base, EQ 0.4 mg base, EQ 0.6 mg base, and EQ 0.8 mg base
Actavis Laboratories FL, Inc. (an indirect, wholly owned subsidiary of Teva Pharmaceuticals USA Inc.), 400 Interpace Parkway, Bldg. A, Parsippany, NJ 07054.( print page 3877)ANDA 207919
Acyclovir Sodium injectable, EQ 50 mg base/mL
Dr. Reddy's Laboratories Inc., 107 College Rd. East, Princeton, NJ 08540.ANDA 209325
Miglustat capsule, 100 mg
Breckenridge Pharmaceutical, Inc., 15 Massirio Dr., Suite 201, Berlin, CT 06037.ANDA 209708
Mivacurium Chloride solution, EQ 10 mg base/5 mL (EQ 2 mg base/mL) and EQ 20 mg base/10 mL (EQ 2 mg base/mL)
Woodward Pharma Services, LLC, 47220 Cartier Dr., Suite A, Wixom, MI 48393.ANDA 211893
Ranitidine HCl capsule, EQ 150 mg base and EQ 300 mg base
Appco Pharma LLC, 262 Old New Brunswick Rd., Suite M, N, B-1, F, Piscataway, NJ 08854.ANDA 214428
Niacin extended-release tablet, 500 mg and 1 g
Sciecure Pharma Inc., U.S. Agent for Beijing Sciecure Pharmaceutical Co., Ltd., 138 Glendale Ave., Edison, NJ 08817.ANDA 215908
Nitisinone capsule, 2 mg, 5 mg, 10 mg, and 20 mg
Torrent Pharma Inc., 106 Allen Rd., Suite 305, Basking Ridge, NJ 07920.ANDA 217094
Fluphenazine HCl tablet, 1 mg, 2.5 mg, 5 mg, and 10 mg
Torrent Pharma Inc., U.S. Agent for Torrent Pharmaceuticals Ltd., 106 Allen Rd., Suite 305, Basking Ridge, NJ 07920.
 Therefore, approval of the applications listed in table 1, and all amendments and supplements thereto, is hereby withdrawn as of February 14, 2025. Approval of each entire application is withdrawn, including any strengths and dosage forms inadvertently missing from table 1. Introduction or delivery for introduction into interstate commerce of products listed in table 1 without an approved new drug application or ANDA violates sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(a) and 331(d)). Drug products that are listed in table 1 that are in inventory on February 14, 2025 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first. Dated: January 8, 2025. P. Ritu Nalubola, Associate Commissioner for Policy.


[FR Doc. 2025-00742 Filed 1-14-25; 8:45 am] BILLING CODE 4164-01-P